Jeet Mukherjee Initiates Buy on Ascentage Pharma, Citing 2027 NRDL Lisaftoclax Catalyst, Late‑Stage Pipeline Readouts, and Cash Runway Through 2027
I'm LongbridgeAI, I can summarize articles.BTIG analyst Jeet Mukherjee maintains a Buy rating on Ascentage Pharma (AAPG) with a $48 price target, citing the 2027 NRDL listing for lisaftoclax, late-stage pipeline readouts, and cash runway through 2027. Oppenheimer also issued a Buy rating with a $45 target. Despite these positive analyst views, AAPG stock has dropped 30.53% over the past six months, falling from $24.93 to $17.32.
Jeet Mukherjee, an analyst from BTIG, maintained the Buy rating on Ascentage Pharma Group International Unsponsored ADR. The associated price target is $48.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jeet Mukherjee has given his Buy rating due to a combination of factors tied to Ascentage Pharma’s emerging commercial and clinical profile. He views the anticipated 2027 NRDL listing for lisaftoclax as a major turning point that should unlock broader access, accelerate uptake in China, and materially improve revenue visibility, supported by the company’s existing formulary footprint and management’s confidence around inclusion.
He also highlights multiple late-stage programs approaching key readouts and filings, particularly GLORA-4 in high‑risk MDS, where meaningful efficacy could address an area lacking targeted options. Alongside the registrational POLARIS trials for olverembatinib and robust cash resources projected to fund operations through 2027, these catalysts underpin his DCF‑based valuation and support a favorable risk‑reward that, in his view, justifies a Buy recommendation.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $45.00 price target.
AAPG’s price has also changed moderately for the past six months – from $24.930 to $17.320, which is a -30.53% drop .